TNR

Tenascin-R (TNR) is a CNS-specific extracellular matrix glycoprotein that functions as a multivalent scaffolding molecule organizing perineuronal nets and modulating neuronal adhesion, neurite outgrowth, and synaptic plasticity. Its fibronectin type III domains 3–5 bind the C-type lectin domains of lecticans (brevican, neurocan, versican, aggrecan) with nanomolar affinity through protein–protein interactions, while its EGF-like repeats engage the neuronal receptor F3/contactin and its fibrinogen-like domain mediates cell adhesion and neuronal polarization (PMID:9294172, PMID:9507007, PMID:9081628). TNR carries the HNK-1 carbohydrate epitope, which regulates perisomatic GABAergic inhibition via GABA_B receptors and thereby sets the metaplastic threshold for hippocampal LTP (PMID:17537973). Biallelic loss-of-function variants in TNR cause an autosomal recessive nonprogressive neurodevelopmental disorder with spastic paresis, axial hypotonia, and movement abnormalities in humans and dogs (PMID:32099069, PMID:37023257).

1. 1996 High

   Systematic domain dissection resolved how TNR's multidomain architecture maps to distinct neuronal functions — the FG domain mediates adhesion and polarization, EGF-like repeats bind the receptor F3/contactin and inhibit neurite outgrowth, and FN III repeats repel neurites — establishing TNR as a multivalent modulator rather than a simple adhesion molecule.

   Evidence Recombinant domain fragment adhesion and neurite outgrowth assays on hippocampal neurons

   PMID:8626505 PMID:9081628

   Open questions at the time

   • Downstream signaling pathways initiated by each domain were not identified
   • Identity of multiple neuronal receptors beyond F3/11 was unresolved
2. 1997 High

   Identification of lecticans as the principal proteoglycan partners of TNR established the molecular basis for ECM network assembly: the C-type lectin domains of brevican, neurocan, versican, and aggrecan bind TNR FN III domains 3–5 via protein–protein interactions, with brevican showing 10-fold higher affinity.

   Evidence Surface plasmon resonance, solid-phase binding, and co-precipitation from rat brain

   PMID:9294172 PMID:9507007

   Open questions at the time

   • Stoichiometry of TNR–lectican complexes in vivo was not determined
   • Structural basis of the differential lectin-domain affinities was unknown
3. 1998 High

   Demonstration that TNR redirects neurofascin-mediated adhesion from NrCAM-dependent to axonin-1/F11-dependent receptor usage revealed TNR as an active modulator of cell-surface receptor switching rather than a passive ECM scaffold.

   Evidence Cellular binding and neurite outgrowth assays with neurofascin splice isoforms and TNR

   PMID:9722619

   Open questions at the time

   • Physiological consequence of receptor switching in vivo was not tested
   • Which neurofascin splice isoforms predominate in PNN-containing brain regions remained unknown
4. 2007 High

   Electrophysiology in TNR-knockout mice answered whether TNR's ECM role translates to synaptic function: loss of TNR reduces perisomatic GABAergic inhibition, increases Ca²⁺ influx and phosphatase activity, and raises the LTP threshold — all rescued by an HNK-1 glycomimetic, pinpointing the HNK-1 epitope as the active moiety acting through GABA_B receptors.

   Evidence Patch-clamp recordings in hippocampal slices from TNR−/− mice with pharmacological and glycomimetic rescue

   PMID:17537973

   Open questions at the time

   • Direct binding of HNK-1 to GABA_B receptor was not demonstrated biochemically
   • Behavioral consequences of the metaplastic shift were not reported
5. 2012 Medium

   Anti-TNR antibody treatment after spinal cord hemisection reduced RhoA activation and improved functional recovery, establishing TNR as a growth-inhibitory ECM component that actively impedes axonal regeneration through Rho signaling.

   Evidence In vitro neurite outgrowth on TNR substrate and in vivo rat spinal cord injury model with antibody administration

   PMID:22902990

   Open questions at the time

   • The receptor transducing TNR's inhibitory signal to RhoA was not identified
   • Single-lab study; independent replication in a second injury model was lacking
6. 2020 Medium

   Exome sequencing in 13 individuals from 8 families demonstrated that biallelic TNR loss-of-function causes a nonprogressive neurodevelopmental disorder with spastic paresis and axial hypotonia, establishing TNR as essential for normal human CNS development.

   Evidence Exome sequencing, matchmaker exchange, clinical phenotyping across 8 unrelated families

   PMID:32099069

   Open questions at the time

   • No functional assays (e.g., patient-derived neurons, protein rescue) validated pathogenicity of specific variants
   • Mechanism linking TNR loss to spasticity versus PNN disruption was inferred, not demonstrated
7. 2023 Medium

   A truncating TNR frameshift in Weimaraner dogs causing paroxysmal dystonia-ataxia extended the genotype–phenotype relationship across species, strengthening the causal link between TNR deficiency and movement disorders.

   Evidence Whole genome sequencing and genotype–phenotype association in a cohort of 74 dogs

   PMID:37023257

   Open questions at the time

   • No histopathological or PNN analysis in affected dog CNS tissue was reported
   • Whether canine phenotype maps to the same circuit (perisomatic inhibition) as the mouse KO was untested
8. 2024 Medium

   Identification of contactin-1 (CNTN1) as the GPI-anchored receptor that immobilizes the TNR–RPTPζ complex on the neuronal surface provided a molecular mechanism for PNN nucleation on specific neuronal subtypes (preprint).

   Evidence Biochemical pulldown and structural analysis of TNR–RPTPζ–CNTN1 complex (preprint)

   Open questions at the time

   • Awaits peer review and independent replication
   • Whether CNTN1 loss phenocopies TNR loss with respect to PNN disruption was not shown in vivo
   • Stoichiometry and structural details of the tripartite complex remain to be resolved at high resolution

• Key unresolved questions include the high-resolution structural basis of TNR–lectican and TNR–RPTPζ interactions, the identity of the neuronal receptor that transduces TNR's growth-inhibitory signal to RhoA, and whether the HNK-1 epitope directly binds GABA_B receptors or acts through an intermediary.
• No crystal or cryo-EM structure of any TNR complex exists
• Direct biochemical evidence for HNK-1–GABA_B receptor binding is absent
• The receptor mediating TNR-dependent RhoA activation is unknown